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Dr Jules Lin (Ann Arbor, Mich). Congratulations on your very
nice presentation. I have several questions that I would like to ask
individually. Het-1A is a normal squamous esophageal cell line.
Why did you choose to use a normal cell line? In your comparison
you looked at 2 tumor cell lines and a normal squamous cell line
looking for a commonality between the 3. Would it have been
more appropriate to compare the tumor cell lines to find something
that was overexpressed when compared to the normal cell line?
Dr Casson. Esophageal cell lines are quite notoriously difficult
to get a hold of. I would question whether Het-1A, which has beenThe Journal of Thoracic and Cararound for 20-odd years, is truly normal at this point. It was orig-
inally derived from normal epithelium but has been immortalized.
We put that in—really as, in quotes—the ‘‘negative control.’’ But,
again, I would caution the interpretation using any of these cell
lines.
Dr Lin. One of the key concepts of CSCs is tumorigenicity.
Out of the 3 cell lines from your data that you presented, 2 of
them formed tumors in the nude mice. The Het-1A did not, for
parent or spheroid cells. However, the 2 markers that you men-
tioned, the Ascl2 and the integrin a6bri/CD71, were both up in
Het-1A. In fact, the integrin a6/CD71 ratio was 21% in Het-
1A and the Ascl2 was up higher than the Johns Hopkins adeno-
carcinoma cell line. What conclusion can you draw about those
markers?
Dr Casson. Your first comment about not being able to grow
Het-1 in animals, that’s consistent with the published data. I
don’t think anybody has been able to reproduce that cell line. So
we really were left with the 2 EADC cell lines for these types of
xenotransplantation experiments.
In terms of the significance of Ascl2 overexpression, at this
point it’s very early. I think what we need to do is reproduce these
results using serial xenograft transplantations along the fairly clas-
sic lines used to determine tumorigenicity using human tissues.
The problem we have, of course, is that the particular marker,
the integrin a6/CD71, the viability of cells based on cell sorting
just does not give you sufficient viability to establish those as xe-
nografts at this point.
Dr Lin. Did you look at any functional studies looking at these
2 genes? Did you try to transfect Ascl2 or integrin a6 to see if it
affects spheroid formation, colony formation, or tumorigenicity?
Dr Casson. No, we haven’t, but that would be the next logical
step.
Dr Lin.My final question: Did you look at any primary tumors
to determine whether either of these markers were overexpressed
in primary tumors?
Dr Casson.We have not looked at the primary tumors. One of
the references I put on from Jan van Lanschot’s lab, that was the
most comprehensive study using primary tumors so far, and, again,
I would say that there were no classic stem cell markers identified
in that series of about 17 tumors. That was reported in the Journal
of Pathology in 2010.
Dr Lin. Thank you. Nice presentation.
Dr Ori Wald (Jerusalem, Israel). I think that another approach
to isolate CSCs might be first to select for chemotherapy resistance
and then to reexamine the markers. I believe that this represents
more what happens in humans. We first treat our patients with che-
motherapy and, as a result, selection for chemotherapy-resistant
cells occurs. By adopting such an approach, this is another ap-
proach you may try to validate the results.
Dr Casson. That’s a good point. I would say that CSC research
for solid tumors, unlike the leukemias, is really in its infancy and
really only has been looked at in the past few years. Good
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